JP2024532503A5 - - Google Patents

Info

Publication number
JP2024532503A5
JP2024532503A5 JP2024514046A JP2024514046A JP2024532503A5 JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5 JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5
Authority
JP
Japan
Prior art keywords
glp
target polypeptide
terminus
fusion protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/116513 external-priority patent/WO2023030444A1/zh
Publication of JP2024532503A publication Critical patent/JP2024532503A/ja
Publication of JP2024532503A5 publication Critical patent/JP2024532503A5/ja
Pending legal-status Critical Current

Links

JP2024514046A 2021-09-02 2022-09-01 Glp-1/gipデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 Pending JP2024532503A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111026970 2021-09-02
CN202111026970.5 2021-09-02
PCT/CN2022/116513 WO2023030444A1 (zh) 2021-09-02 2022-09-01 Glp-1/gip双靶多肽、融合蛋白及其应用

Publications (2)

Publication Number Publication Date
JP2024532503A JP2024532503A (ja) 2024-09-05
JP2024532503A5 true JP2024532503A5 (cg-RX-API-DMAC7.html) 2025-08-14

Family

ID=85411955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514046A Pending JP2024532503A (ja) 2021-09-02 2022-09-01 Glp-1/gipデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用

Country Status (5)

Country Link
US (1) US20250223331A1 (cg-RX-API-DMAC7.html)
EP (1) EP4410827A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532503A (cg-RX-API-DMAC7.html)
CN (1) CN115850437A (cg-RX-API-DMAC7.html)
WO (1) WO2023030444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
KR20240007251A (ko) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
KR20250140132A (ko) * 2023-01-18 2025-09-24 상하이 민웨이 바이오테크놀로지 씨오 엘티디 삼중 활성을 갖는 융합 단백질 및 그 용도
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity
CN120829494A (zh) * 2024-04-18 2025-10-24 苏州星曜坤泽生物制药有限公司 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用
WO2026046352A1 (zh) * 2024-08-30 2026-03-05 石药集团巨石生物制药有限公司 一种gip/glp-1受体共激动剂及其应用
WO2026076425A1 (en) 2024-10-04 2026-04-09 Biodrive, Inc. Oral biodelivery platform
CN118955739B (zh) * 2024-10-17 2025-02-18 华南理工大学 一种双靶点受体激动剂融合蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558842T3 (es) * 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
WO2013003449A2 (en) * 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MX2014015557A (es) * 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
CA2929459C (en) * 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
CN111111264A (zh) * 2019-12-31 2020-05-08 杭州九源基因工程有限公司 制备多肽步骤中色谱固定相的再生方法
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP7461438B2 (ja) 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US9260496B2 (en) Fibronectin based scaffold domain proteins that bind IL-23
ES2328510T3 (es) Proteinas de fusion glp-1.
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
Chen et al. Fusion protein linkers: property, design and functionality
ES2842677T3 (es) Ligandos modificados mediante permutación circular como agonistas y antagonistas
JP2023518596A5 (cg-RX-API-DMAC7.html)
JP2011501959A5 (cg-RX-API-DMAC7.html)
JP2018171063A5 (cg-RX-API-DMAC7.html)
AU2017273743B2 (en) Serum albumin-binding fibronectin type III domains
JP2012505902A5 (cg-RX-API-DMAC7.html)
JP2018515088A5 (cg-RX-API-DMAC7.html)
JP2005514060A5 (cg-RX-API-DMAC7.html)
JP2023505492A5 (cg-RX-API-DMAC7.html)
JP2008507298A5 (cg-RX-API-DMAC7.html)
JP2022522787A5 (cg-RX-API-DMAC7.html)
JP2020517260A5 (cg-RX-API-DMAC7.html)
JP2024532503A (ja) Glp-1/gipデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用
JP2025512865A5 (cg-RX-API-DMAC7.html)
CN111234015B (zh) 用于延长药物半衰期的抗体、其融合蛋白和应用
JP2025124904A5 (cg-RX-API-DMAC7.html)
JP2024038140A5 (cg-RX-API-DMAC7.html)
JP2023524981A5 (cg-RX-API-DMAC7.html)
JP2008528004A5 (cg-RX-API-DMAC7.html)
JP2024526356A5 (cg-RX-API-DMAC7.html)